Literature DB >> 21140282

Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma.

Giuseppe Lombardi1, Fable Zustovich, Alessandro Della Puppa, Lucia Borgato, Enrico Orvieto, Renzo Manara, Diego Cecchin, Franco Berti, Patrizia Farina, Marina Paolo Gardiman, Renato Scienza, Vittorina Zagonel.   

Abstract

Intestinal-type adenocarcinoma of the nasal cavities and paranasal sinuses is a relatively rare tumor. Standard therapeutic modalities include surgery followed by radiotherapy, sometimes with chemotherapy treatment. Despite these treatments, the outcome is poor due to frequent local recurrences constituting the main cause of death among patients; leptomeningeal carcinomatosis is not a frequent event, and its presence indicates short expected survival. The therapy of neoplastic meningitis includes cranial irradiation, intrathecal chemotherapy and high-dose systemic chemotherapy. However, these approaches report important side effects with only modest efficacy. Thus, it is important to discover better treatment for this cancer complication. We present, for the first time, a case of leptomeningeal carcinomatosis from invasive intestinal-type adenocarcinoma treated with temozolomide and cisplatin chemotherapy obtaining a prolonged reduction and stabilization of the lesion improving the clinical condition of the patient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21140282     DOI: 10.1007/s11060-010-0484-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study.

Authors:  W Boogerd; M J van den Bent; P J Koehler; J J Heimans; J J van der Sande; N K Aaronson; A A M Hart; J Benraadt; Ch J Vecht
Journal:  Eur J Cancer       Date:  2004-12       Impact factor: 9.162

2.  Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.

Authors:  L Licitra; S Suardi; P Bossi; L D Locati; L Mariani; P Quattrone; S Lo Vullo; M Oggionni; P Olmi; G Cantù; M A Pierotti; S Pilotti
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

3.  [Leptomeningeal dissemination after ethmoidal sinus adenocarcinoma surgery: a rare complication].

Authors:  Y Béjot; A Catteau; M Hervieu; P Giré; M Caillier; I Bénatru; G-V Osseby; P Soichot; T Moreau; M Giroud
Journal:  Rev Neurol (Paris)       Date:  2008-01-31       Impact factor: 2.607

Review 4.  Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.

Authors:  E S Newlands; M F Stevens; S R Wedge; R T Wheelhouse; C Brock
Journal:  Cancer Treat Rev       Date:  1997-01       Impact factor: 12.111

5.  A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.

Authors:  C D Britten; E K Rowinsky; S D Baker; S S Agarwala; J R Eckardt; R Barrington; S G Diab; L A Hammond; T Johnson; M Villalona-Calero; U Fraass; P Statkevich; D D Von Hoff; S G Eckhardt
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

6.  Leptomeningeal carcinomatosis following craniofacial resection of an ethmoid tumor.

Authors:  B C Wen; D H Hussey; G H Clamon; J C Godersky
Journal:  J Surg Oncol       Date:  1992-04       Impact factor: 3.454

7.  A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.

Authors:  Fable Zustovich; Giuseppe Lombardi; Alessandro Della Puppa; Antonino Rotilio; Renato Scienza; Davide Pastorelli
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

8.  Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.

Authors:  Sandrine Ostermann; Chantal Csajka; Thierry Buclin; Serge Leyvraz; Ferdy Lejeune; Laurent A Decosterd; Roger Stupp
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.

Authors:  S A Grossman; D M Finkelstein; J C Ruckdeschel; D L Trump; T Moynihan; D S Ettinger
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

10.  A case of intestinal-type sinonasal adenocarcinoma.

Authors:  Carlos Robles; Eugene M Cooper
Journal:  J Natl Med Assoc       Date:  2004-01       Impact factor: 1.798

View more
  5 in total

1.  Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.

Authors:  Pedro Pérez Segura; Miguel Gil; Carmen Balañá; Ignacio Chacón; José Muñoz Langa; María Martín; Jordi Bruna
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

Review 2.  Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches.

Authors:  Giuseppe Lombardi; Fable Zustovich; Patrizia Farina; Alessandro Della Puppa; Renzo Manara; Diego Cecchin; Antonella Brunello; Alessandro Cappetta; Vittorina Zagonel
Journal:  Oncologist       Date:  2011-07-27

3.  Primary Intestinal-type Adenocarcinoma of the Nasal Cavity: A Case Report.

Authors:  S Belli; U Taskin; A Caglar; U S Tetikkurt
Journal:  West Indian Med J       Date:  2014-05-08       Impact factor: 0.171

Review 4.  Leptomeningeal carcinomatosis from gastric cancer successfully treated by the intrathecal methotrexate plus temozolomide and simultaneous radiotherapy: Case report and literatures review.

Authors:  Yangyang Liu
Journal:  Cancer Biol Ther       Date:  2017-09-07       Impact factor: 4.742

Review 5.  Leptomeningeal disease: current diagnostic and therapeutic strategies.

Authors:  Gautam Nayar; Tiffany Ejikeme; Pakawat Chongsathidkiet; Aladine A Elsamadicy; Kimberly L Blackwell; Jeffrey M Clarke; Shivanand P Lad; Peter E Fecci
Journal:  Oncotarget       Date:  2017-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.